Abstract
Most sq-NSCLC patients were aged, heavy somkers, with multiple comorbidities who were considered badly-tolerated to chemotherapy. We designed this multi-center, single arm, phase II study of sintilimab plus two cycles nab-paclitaxel /carboplatin in treatment naïve advanced squamous NSCLC patients, aimed to maximize the antitumor activities with less toxicity.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
